Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells

European Journal of Pharmacology

Volumn 341, Issue 2-3, 1998, Pages 309-315

  Nauck, Markus ^a   Karakiulakis, George ^b   Perruchoud, André P ^c   Papakonstantinou, Eleni ^b   Roth, Michael ^c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c Univ H   (Switzerland)

Author keywords

Anti angiogenic; Corticosteroid; Desoxycorticosterone; Pregnenolone; VEGF (vascular endothelial growth factor)

Indexed keywords

CORTICOSTEROID; CORTISONE; DEOXYCORTICOSTERONE; DEXAMETHASONE; HEPARIN; HYDROCORTISONE; PLATELET DERIVED GROWTH FACTOR; PREGNENOLONE; RNA; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; EDEMA; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR SMOOTH MUSCLE;

ANTI-INFLAMMATORY AGENTS; CORTISONE; DEXAMETHASONE; ENDOTHELIAL GROWTH FACTORS; HUMANS; HYDROCORTISONE; LYMPHOKINES; MUSCLE, SMOOTH, VASCULAR; PLATELET-DERIVED GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032509788     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01464-7     Document Type: Article

References (40)

1. Auerbach W., Auerbach R. Angiogenesis inhibition: A review. Pharmacol. Ther. 63:1994;265-311.
2. Brogi E., Wu T., Namiki A., Isner J.M. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation. 90:1994;649-652.
3. Brown L.F., Detmar M., Tognazzi K., Abu-Jawdeh G., Iruela-Arispe M.-L. Uterine smooth muscle cells express functional receptors (flt-1 and KDR) for vascular permeability factor/vascular endothelial growth factor. Lab. Invest. 76:1997;245-255.
4. Chomczynski H., Sacchi N. Single-step method of RNA isolation by acid guanidinium isothiocyanate phenol chloroform extraction. Anal. Biochem. 162:1987;156-159.
5. Criscuolo G.R. The genesis of peritumoral vasogenic brain edema and tumor cysts: A hypothetical role for tumor-derived vascular permeability factor. Yale J. Biol. Med. 66:1993;277-283.
6. De Vries C., Escobedo J.A., Ueno H., Houck K., Ferrara N., Williams L.T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 255:1992;989-991.
7. Ferrara N., Henzel W.J. Pituitary follicular cells secret a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161:1989;851-858.
8. Flamme I., Breier G., Risau W. Overexpression of vascular endothelial growth factor in the avian embryo induces hypervascularization and increased vascular permeability without alterations of embryonic pattern formation. Dev. Biol. 169:1995;699-712.
9. Folkman J. Anti-angiogenesis: New concept for tumor therapy of solid tumors. Ann. Surg. 175:1972;409-502.
10. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1:1995;27-31.
11. Folkman J., Ingber D.E. Angiostatic steroids. Ann. Surg. 206:1987;374-383.
12. Folkman J., Haudenschild C., Langer R., Linhardt R.J., Taylor S. Angiogenesis inhibition and tumor-regression caused by heparin or a heparin fragment in the presence of cortisone. Science. 221:1983;719-725.
13. Frank S., Hubner G., Breier G., Longaker M.T., Greenhalgh D.G., Werner S. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J. Biol. Chem. 270:1995;12607-12613.
14. 165 using several concurrent mechanisms. J. Biol. Chem. 270:1995;15059-15065.
15. Gospodarowicz D., Abraham J.A., Schilling J. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived follicular stellate cells. Proc. Natl. Acad. Sci. USA. 86:1989;7311-7315.
16. 1 in osteoblasts. J. Clin. Invest. 93:1994;2490-2496.
17. Haynes, R.C., 1992. Adrenocorticotropic hormone, adrenocortical steroids and their synthetic analogs: Inhibitors of the synthesis and actions of adrenocortical hormones. In: Goodman-Gilman, A., Rall, T.W., Nies, A.S., Taylor, P. (Eds.), The Pharmacological Basis of Therapeutics, 8th ed. McGraw-Hill, New York, pp. 1431-1435.
18. Jellinek D., Green L.S., Bell C., Janjic N. Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor. Biochemistry. 33:1994;10450-10456.
19. Keck P.J., Hauser S.D., Krivi G., Sanzo K., Warren T., Feder J., Connolly T.D. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 246:1989;1309-1315.
20. Koch A.E., Harlow L.A., Haines G.K., Amento G.H., Unemori E.N., Wong W.L., Pope R.M., Ferrara N. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J. Immunol. 152:1994;4149-4156.
21. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.H., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246:1989;1306-1311.
22. Levy A.P., Levy A.S., Loscalzo J., Calderone A., Takahashi N., Yeo K.T., Koren G., Colucci W.S., Goldberg M.A. Regulation of endothelial growth factor in cardiac myocytes. Circ. Res. 76:1995;758-766.
23. Maragoudakis M.E., Sarmonika M., Panoutsacopoulou M. Anti-angiogenic action of heparin plus cortisone is associated with decreased collagenous protein synthesis in the chick chorioallantoic membrane system. J. Pharmacol. Exp. Ther. 251:1989;679-684.
24. Maragoudakis M.E., Missirlis E., Sarmonika M., Panoutsacopoulou M., Karakiulakis G. Basement membrane biosynthesis as a target to tumor therapy. J. Pharmacol. Exp. Ther. 252:1990;753-757.
25. Maragoudakis, M.E., Gullino, P., Lelkes, P.I. (Eds.), 1992. Angiogenesis in Health and Disease. Plenum Press, New York.
26. Maragoudakis M.E., Missirlis E., Karakiulakis G., Sarmonika M., Bastaki M., Tsopanoglou N. Basement membrane biosynthesis as a target for developing inhibitors of angiogenesis with anti-tumor properties. Kidney Int. 43:1993;147-150.
27. Millauer B., Shawver L.K., Plate K.H., Risau W., Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature. 367:1994;576-579.
28. Neufeld G., Tessler S., Gitay-Goren H., Cohen T., Levi B.Z. Vascular endothelial growth factor and its receptors. Prog. Growth Factor Res. 5:1994;89-95.
29. Pertovaara L., Kaipainen A., Mustonen T., Orpana A., Ferrara N., Saksela O., Alitalo K. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J. Biol. Chem. 269:1994;6271-6274.
30. Pipili-Synetos E., Papageorgiou A., Sakkoula E., Sotiropoulou G., Fotsis T., Karakiulakis G., Maragoudakis M.E. Inhibition of angiogenesis, tumour growth and metastasis by the NO-releasing vasodilators, isosorbide mononitrate and dinitrate. Br. J. Pharmacol. 116:1995;1829-1834.
31. Roth M., Emmons L.R., Perruchoud A.P., Block L.H. Expressions of the low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase genes are stimulated by recombinant platelet-derived growth factor isomers. Proc. Natl. Acad. Sci. USA. 88:1991;1888-1892.
32. Roth M., Nauck M., Yousefi S., Tamm M., Blaser K., Perruchoud A.P., Simon H.-U. Platelet-activating factor exerts mitogenic activity and stimulates expression of interleukin-6 and interleukin-8 in human lung fibroblasts via binding to its functional receptor. J. Exp. Med. 184:1996;191-201.
33. Shifren J.L., Doldi N., Ferrara N., Mesiano S., Jaffe R.B. In the human fetus, vascular endothelial growth factor is expressed in epithelial cells and myocytes, but not vascular endothelium: Implications for mode of action. J. Clin. Endocrinol. Metab. 79:1994;316-322.
34. 2-macroglobulin and the binding is inhibited by heparin. J. Biol. Chem. 268:1993;7685-7691.
35. Stavri G.T., Hong Y., Zachary I.C., Breier G., Baskerville P.A., Yla-Herttuala S., Risau W., Martin J.F., Erusalimsky J.D. Hypoxia and platelet-derived growth factor-BB synergistically upregulate the expression of vascular endothelial growth factor in vascular smooth muscle cells. FEBS Lett. 358:1995;311-315.
36. Stein I., Neeman M., Shweiki D., Itin A., Keshet D. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. Mol. Cell Biol. 15:1995;5363-5368.
37. Stokes C.L., Weisz P.B., Williams P.S., Lauffenburger D.A. Inhibition of microvascular endothelial cell migration by ,-cyclodextrin tetradecasulfate and hydrocortisone. Microvasc. Res. 40:1990;279-284.
38. Takeshita S., Zheng L.P., Brogi E., Kearney M., Pu L.Q., Bunting S., Ferrara N., Symes J.F., Isner J.M. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J. Clin. Invest. 93:1994;662-670.
39. Tischer E., Mitchell R., Hartman T., Silva M., Gospodarowicz D., Fiddes J.D., Abraham J.A. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266:1991;1947-1954.
40. Wizigmann-Voos S., Breier G., Risau W., Plate K.H. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res. 55:1995;1358-1364.